中国P站

Mucosal vaccine; Vaccine delivery; Adjuvants; Nanoparticles; Intranasal vaccine; Sublingual vaccine; Microneedles; Outer Membrane Vesicles; Dendritic cells; Computational modeling

Introduction

Mucosal vaccine delivery has garnered significant attention for its potential to induce robust immune responses at the site of pathogen entry[1].

Recent advances in this field explore particulate carriers like liposomes and nanoparticles to enhance antigen uptake and improve vaccine efficacy[1].

Intranasal administration of vaccines, particularly those using chitosan-based delivery systems, demonstrates promising results in eliciting both mucosal and systemic immunity, offering enhanced protection against infections like influenza[2].

Bacterial Outer Membrane Vesicles (OMVs) are emerging as versatile platforms for mucosal vaccine development, effectively inducing mucosal immunity and protecting against bacterial infections through robust antibody responses[3].

Plant-based expression systems present cost-effective and scalable solutions for producing mucosal vaccines, with oral delivery formulations capable of inducing mucosal immunity[4].

Sublingual vaccines are also being explored, with studies showing that they can induce potent mucosal and systemic immune responses, providing protection comparable to intramuscular vaccination against influenza[5].

Microneedles offer a minimally invasive approach to deliver vaccines directly to mucosal tissues, enhancing antigen presentation and immune responses, leading to robust immunity[6].

Adjuvants play a crucial role in enhancing the immunogenicity of mucosal vaccines by stimulating innate immune responses and promoting antigen uptake and presentation[7].

Computational modeling aids in optimizing mucosal vaccine delivery by simulating vaccine transport and distribution in mucosal tissues, providing insights into factors influencing vaccine efficacy[8].

Dendritic cell-targeted mucosal vaccines enhance antigen presentation and induce potent immune responses, demonstrating improved vaccine efficacy and long-lasting immunity[9].

Finally, the development of mucosal vaccines against respiratory viruses faces challenges, but various strategies, including novel adjuvants and delivery systems, aim to enhance vaccine efficacy and induce both mucosal and systemic immunity for optimal protection[10].

Description

Mucosal vaccine delivery systems represent a promising frontier in immunization strategies, offering the potential to induce robust and targeted immune responses at the body's entry points for pathogens. Traditional injectable vaccines often elicit systemic immunity, which may not be sufficient to combat infections that primarily occur at mucosal surfaces such as the respiratory or gastrointestinal tracts. Mucosal vaccines, on the other hand, can stimulate both mucosal and systemic immunity, providing a more comprehensive defense against a wide range of infectious diseases[1, 10].

Several innovative approaches are being explored to enhance the efficacy of mucosal vaccines. Particulate carriers, such as liposomes and nanoparticles, are utilized to improve antigen uptake and delivery to immune cells within mucosal tissues[1]. These carriers protect the antigen from degradation and facilitate its transport across mucosal barriers. Adjuvants, which are substances that enhance the immune response, also play a critical role in mucosal vaccine formulations by stimulating innate immune responses and promoting antigen presentation[7].

Different routes of mucosal vaccine administration are being investigated, including intranasal, sublingual, and oral delivery. Intranasal vaccines have shown promise in eliciting broadly protective immunity against respiratory viruses like influenza, particularly when combined with chitosan-based delivery systems[2]. Sublingual vaccines offer a non-invasive alternative, demonstrating the ability to induce potent mucosal and systemic immune responses comparable to intramuscular vaccination[5]. Plant-based expression systems provide a cost-effective and scalable platform for producing mucosal vaccines suitable for oral delivery[4].

Emerging technologies, such as microneedles and bacterial outer membrane vesicles (OMVs), are also revolutionizing mucosal vaccine delivery. Microneedles offer a minimally invasive approach to deliver vaccines directly to mucosal tissues, enhancing antigen presentation and immune responses[6]. OMVs derived from bacteria can serve as versatile platforms for delivering antigens and inducing robust antibody responses against bacterial infections[3]. Furthermore, computational modeling is being employed to optimize mucosal vaccine delivery by simulating vaccine transport and distribution in mucosal tissues, aiding in the design of more effective delivery strategies[8]. Dendritic cell-targeted mucosal vaccines represent another promising avenue, enhancing antigen presentation and inducing potent immune responses[9].

Conclusion

Mucosal vaccine delivery systems are gaining prominence as a strategy to induce targeted immune responses at pathogen entry sites. Various innovative approaches are being explored to enhance vaccine efficacy, including particulate carriers like liposomes and nanoparticles, which improve antigen uptake and delivery within mucosal tissues. Adjuvants play a crucial role by stimulating innate immune responses and promoting antigen presentation. Different administration routes such as intranasal, sublingual, and oral are being investigated, with intranasal vaccines showing promise against respiratory viruses when combined with chitosan-based delivery systems, and sublingual vaccines offering a non-invasive alternative. Plant-based expression systems provide a cost-effective platform for oral vaccines. Emerging technologies like microneedles and bacterial outer membrane vesicles (OMVs) are revolutionizing delivery, with microneedles offering minimally invasive delivery and OMVs serving as versatile antigen delivery platforms. Computational modeling aids in optimizing delivery strategies, and dendritic cell-targeted vaccines enhance antigen presentation and immune responses. The development of mucosal vaccines against respiratory viruses involves strategies to enhance vaccine efficacy and induce both mucosal and systemic immunity.

References

1. Rajan N, Anurag B, Bishnu KP (2022) .Pharmaceutics 14:2483.

   , ,

2. Thomas MR, Ilhem B, Trent SM (2020) .JCI Insight 5:e135023.

   , ,

3. Lei C, Tian X, Yuxin Z (2021) .J Control Release 338:787-800.

   , ,

4. Azin D, Saurabh K, Ashok KV (2019) .Biotechnol Adv 37:107415.

   , ,

5. Do YK, Yun SJ, Yun SL (2023) .Vaccine 41:2453-2462.

   , ,

6. Eneko L, Cameron JS, Emma E (2019) .Adv Drug Deliv Rev 139:79-97.

   , ,

7. Edel CL, Rachel WW (2016) .Nat Rev Immunol 16:213-226.

   , ,

8. Rosaria V, Alessandra C, Alessandra R (2020) .Adv Drug Deliv Rev 157:187-204.

   , ,

9. Wei M, Patrick GH, Daniel HS (2018) .Adv Drug Deliv Rev 114:47-61.

   , ,

10. Megan M, Karin N (2020) .J Control Release 325:141-155.

    , ,